Back in late August we initiated on Dimerix (ASX: DXB), a drug discovery company being built around new ways to identify highly valuable drug targets known as G Protein-Coupled Receptors. We've updated our coverage of Dimerix with a note on some recent data, which we think are very encouraging, from the company's first clinical study of DMX-200, its lead candidate. DMX-200 combines two existing drugs, irbesartan and propagermanium. The product is now in a Phase II study in patients with proteinuria, symptomatic of a range of kidney problems. Following guidance for the FDA, Dimerix is now making plans to take DMX-200 into a pivotal study in Focal Segmental Glomerulosclerosis, an Orphan kidney disease. Dimerix reported on 4 October that 21 out of 30 patients have now been dosed in this study. Of 11 patients at or past the study mid-point, three have shown a ~ 50% reduction or greater in proteinuria over and above standard of care, which is very encouraging. Final data from Part A of the Phase 2 study is expected in the second half of next year.